Neurocrine Biosciences
NBIX
#1275
Rank
$13.54 B
Marketcap
$134.57
Share price
0.37%
Change (1 day)
37.53%
Change (1 year)
Neurocrine Biosciences is an American biopharmaceutical company that develops treatments for neurological and endocrine-related diseases and disorders.

P/E ratio for Neurocrine Biosciences (NBIX)

P/E ratio as of June 2024 (TTM): 68.9

According to Neurocrine Biosciences 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 68.8571. At the end of 2022 the company had a P/E ratio of 74.2.

P/E ratio history for Neurocrine Biosciences from 2001 to 2023

PE ratio at the end of each year

Year P/E ratio Change
202274.2-17.25%
202189.7307.81%
202022.0-91.82%
2019269-17.21%
2018325-781.9%
2017-47.699.26%
2016-23.9-56.5%
2015-54.9101.59%
2014-27.2101.27%
2013-13.5-112.67%
2012107754.86%
201112.5-127.81%
2010-44.92047.92%
2009-2.0950.38%
2008-1.3967.02%
2007-0.8330-77.38%
2006-3.68-96.48%
2005-105169.33%
2004-38.8-33.81%
2003-58.6298.16%
2002-14.7-59.24%
2001-36.1

P/E ratio for similar companies or competitors

Company P/E ratio P/E ratio differencediff. Country
14.9-78.31%๐Ÿ‡บ๐Ÿ‡ธ USA
46.6-32.26%๐Ÿ‡บ๐Ÿ‡ธ USA
163 136.66%๐Ÿ‡บ๐Ÿ‡ธ USA
58.9-14.46%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.0045-100.01%๐Ÿ‡บ๐Ÿ‡ธ USA
-126-282.89%๐Ÿ‡บ๐Ÿ‡ธ USA
-0.6486-100.94%๐Ÿ‡บ๐Ÿ‡ธ USA
48.5-29.59%๐Ÿ‡ฌ๐Ÿ‡ง UK

How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.